News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Innovimmune Biotherapeutics, Inc.'s Preclinical Data On Highly Selective ROR Gamma Inhibitor Prevents Multiple Sclerosis In Mice



1/15/2014 8:09:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Jan. 15, 2014 (GLOBE NEWSWIRE) -- Specialty drug discovery company, Innovimmune Biotherapeutics Holding, LLC presented data at the XXI World Congress of Neurology in Vienna, Austria (September 22-24, 2013) that demonstrated robust efficacy in preventing multiple sclerosis [MS] in a preclinical mouse model following treatment with its proprietary oral small molecule Retinoic acid receptor-related Orphan Receptor ROR gamma (t) [ROR gamma t] modulators from their INV-17 portfolio.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES